SCHEMBL5887196

SCHEMBL5887196

Cc1ccc(C2=C(Cl)C(Cl)=CC[CH]2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 3/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
RECQL P46063 1/20 0.34
RAB9A P51151 1/20 0.34
MDM2 Q00987 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PTGS2 P35354 1/20 0.32
ACHE P22303 1/20 0.31
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811189 0.79 PTGS2 (0.38) HPGDCYP2D6CYP2C9ALOX15CYP2C19
SCHEMBL6047649 0.79 L3MBTL1 (0.38) HPGDL3MBTL1RAB9AACHEMEN1
SCHEMBL5887070 0.74 ACHE (0.44) HPGDTDP1KDM4EMAPTRAB9A
SCHEMBL5887433 0.74 ACHE (0.44) HPGDCYP2D6CYP2C9ALOX15CYP2C19
SCHEMBL5886998 0.73 ALDH1A1 (0.33) HPGDCYP2D6CYP2C9ALOX15CYP2C19
SCHEMBL5887212 0.72 ALKBH3 (0.39) HPGDCYP2D6CYP2C9ALOX15CYP2C19
SCHEMBL4159444 0.72 PTGS2 (0.38) TDP1MAPTPOLBNPSR1PTGS2
SCHEMBL4009121 0.71 ALDH1A1 (0.33) TDP1MAPTACHEMEN1ALDH1A1
SCHEMBL4808757 0.70 ESR2 (0.39) CYP2C9CYP2C19MAPTMEN1KMT2A
SCHEMBL4805089 0.69 TDP1 (0.34) HPGDCYP2D6CYP2C9ALOX15CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R HPGD 1690/4885CYP2D6 388/4885CYP2C9 272/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R HPGD 1666/4885CYP2D6 1004/4885CYP2C9 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.